Abstract
Uterine leiomyosarcoma is a malignant neoplasm originating from smooth muscle cells.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSuggested Readings
Ben-Ami (2017) Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study. Cancer 123(17):3285–3290
Benson (2016) Outcome of uterine sarcoma patients treated with pazopanib: a retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62,043 and 62,072. Gynecol Oncol 142(1):89–94
Bizzarri (2019) Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study. Int J Gynecol Cancer 29(7):1134–1140
Cybulska (2019) Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. Gynecol Oncol 154(2):333–337
Demetri (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34(8):786–793
Friedman (2018) Options for adjuvant therapy for uterine leiomyosarcoma. Curr Treat Options in Oncol 19(2):7
Gadducci (2018) A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. Br J Cancer 119(5):565–571
George (2017) Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 46(2):197–204
Hensley (2017) Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol 146(3):531–537
Hensley (2018) Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG oncology/Gynecologic Oncology Group Study. J Clin Oncol [Epub ahead of print]
Meng (2020) Construction and validation of nomograms for predicting the prognosis of uterine leiomyosarcoma: a population-based study. Med Sci Monit 26:e922739
Reed (2008) Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European organisation for research and treatment of cancer gynaecological cancer group study (protocol 55,874). Eur J Cancer 44(6):808–818
Roberts (2018) Uterine leiomyosarcoma: a review of the literature and update on management options. Gynecol Oncol 151(3):562–572
Sun (2019) How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagn Interv Imaging 100(10):619–634
Yuan (2019) Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study. BMC Cancer 19(1):697
Zang (2019) Hormonal therapy in uterine sarcomas. Cancer Med 8:1339–1349
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Mocellin, S. (2021). Uterine Leiomyosarcoma. In: Soft Tissue Tumors . Springer, Cham. https://doi.org/10.1007/978-3-030-58710-9_250
Download citation
DOI: https://doi.org/10.1007/978-3-030-58710-9_250
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-58709-3
Online ISBN: 978-3-030-58710-9
eBook Packages: MedicineMedicine (R0)